Skip to content
AnalystLens

Exelixis Annual Report, Year Ended Dec 31, 2000

Filing Date
Filed March 15, 2001
Period End
December 31, 2000
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed March 15, 2001. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. reported a 2000 net loss of $75.3 milliona on total revenues of $24.8 million, up from $10.5 million in 1999 and $2.3 million in 1998.

The loss was driven largely by a $38.1 millionb charge for acquired in-process research and development tied to the December 2000 acquisition of Agritope, Inc., which was renamed Exelixis Plant Sciences, and by research and development expenses of $48.5 million and selling, general and administrative expenses of $18.9 million. The company says it is a leader in discovering novel drug targets, particularly for cancer, using comparative genomics and model system genetics, and it relies on collaborations with Bayer, Pharmacia, Bristol-Myers Squibb, Dow AgroSciences and Aventis CropScience for funding. Bayer and Pharmacia accounted for approximately 53% and 36% of 2000 revenues, respectively.

As of December 31, 2000, cash, cash equivalents and short-term investments totaled $112.6 millionc, following the May 2000 initial public offering with net proceeds of approximately $127.5 million. Stockholders' equity rose to $162.7 million from a deficit of $49.6 million a year earlier, and the accumulated deficit reached $130.0 million.

Management states that current resources should sustain planned operations for at least the next two years, while also warning that it expects continuing losses and may need additional capital. The filing also highlights significant risks: heavy dependence on a small number of collaborators whose agreements have varying expiration and termination provisions, an early-stage technology platform with no proprietary product commercialization experience, and a stock price that closed at $8.75d on March 12, 2001, compared with a 2000 quarterly high of $49.25.

Key Highlights

  1. Total revenues of $24.8 million in 2000, up from $10.5 million in 1999 and $2.3 million in 1998
  2. Net loss of $75.3 million in 2000, or $2.43 per share, including a $38.1 million in-process R&D charge from the Agritope acquisition
  3. Bayer accounted for approximately 53% of 2000 revenues and Pharmacia for approximately 36%
  4. Cash, cash equivalents and short-term investments of $112.6 million at December 31, 2000, after a May 2000 IPO with net proceeds of about $127.5 million
  5. Stockholders' equity of $162.7 million at year-end 2000, compared with a deficit of $49.6 million in 1999
  6. Management expects current resources to fund planned operations for at least the next two years
  7. Accumulated deficit of $130.0 million; the company expects continued operating losses

Frequently Asked Questions

  1. How much revenue did Exelixis generate, and where did it come from?

    Total revenues were $24.8 million in 2000, consisting of $3.8 million in license revenue and $21.0 million in contract and government grant revenue. Bayer accounted for approximately 53% of revenues and Pharmacia for approximately 36%.

  2. Why was the 2000 net loss so large?

    The net loss of $75.3 million included a $38.1 million charge for acquired in-process research and development from the Agritope acquisition, along with research and development expenses of $48.5 million, SG&A of $18.9 million, and non-cash stock compensation amortization of $14.0 million.

  3. How much cash does Exelixis have and how long will it last?

    Cash, cash equivalents and short-term investments totaled $112.6 million at December 31, 2000. Management believes this, together with collaborator funding, will be sufficient for at least the next two years, though it may seek additional financing.

  4. What are the main risks for investors?

    Key risks include dependence on a few collaborators, several of which have agreements expiring or terminable within the next few years; a Pharmacia research restructuring that may reduce funding after the first quarter of 2002; unproven technologies with no proprietary product commercialization experience; substantial continuing losses; and a volatile stock price, which closed at $8.75 on March 12, 2001.

  5. What is the company's strategy?

    Exelixis aims to discover novel drug targets, especially for cancer, through its integrated platform of comparative genomics, model system genetics and compound libraries exceeding one million small molecules, while partnering with major pharmaceutical and agricultural companies to fund research and share future milestones and royalties.